3rd May 2023 19:22
GSK PLC - Brentford, London-based pharmaceutical firm - Announces the US Food & Drug Administration approves Arexvy, the world's first respiratory syncytial virus vaccine for older adults. States approval enables adults aged 60 years and older to be protected from RSV disease for the first time. Explains the approval is based on data from the positive pivotal AReSVi-006 phase III trial that showed exceptional efficacy in older adults, including those with underlying medical conditions, and in those with severe RSV disease. Plans US launch before the 2023/24 RSV season.
Current stock price: 1,457.40 pence, up 0.2% in London on Wednesday
12-month change: down 19%
By Jeremy Cutler, Alliance News reporter
Comments and questions to [email protected]
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Related Shares:
Glaxosmithkline